Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Cassava Sciences Inc (NQ: SAVA )

28.14 -4.04 (-12.55%)
Streaming Delayed Price Updated: 11:40 AM EST, Nov 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Cassava Sciences Inc

< Previous 1 2
...
27 28 29 30 31 32 33 34 Next >
The Daily Biotech Pulse: Sanofi, Translate Bio Start Early Stage Seasonal Flu Vaccine Study, Dr. Reddy's Launches Generic Vascepa, Halozyme Strikes Licensing Deal
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 21) Agios Pharmaceuticals, Inc... 
Via Benzinga
Why Cassava Sciences Stock Soared Today
Investors applauded the company's update on its clinical programs. 
Via The Motley Fool
Why Cassava Sciences Shares Are Moving Today
Cassava Sciences Inc (NASDAQ:SAVA) shares are trading high... 
Via Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
Gainers Anavex Life Sciences (NASDAQ:AVXL) shares moved upwards by 17.07% to $25.92 during Monday's regular session. Anavex Life Sciences's stock is trading at a... 
Via Benzinga
Cassava Sciences Stock Gains After Outlining Clinical Development Progress For Lead Alzheimer's Candidate
Cassava Sciences Inc (NASDAQ: SAVA) has announced a mid-year update highlighting clinical development progress and providing guidance on upcoming data releases for... 
Via Benzinga
These 2 Biotech Stocks Are Up 1,000% This Year
New approaches to treating Alzheimer's could mean even bigger gains in the future. 
Via The Motley Fool
Why Anavex Stock Nearly Round-Tripped Its Double-Digit Gain This Week
Researchers featured a pair of Anavex Life Sciences drugs in a paper on Alzheimer's disease this week, but AVXL stock plunged on Tuesday. 
Via Investor's Business Daily
Where Will Biogen Be in 1 Year?
The controversy never ends with this biotech's new Alzheimer's drug. 
Via The Motley Fool
Exposures Product Safety
Tuesday Talk: Action!
U.S. stock markets started the week in continued action mode. The S&P 500 closed at 4,255, up nearly 8 points, the Dow closed at 34,394, down 85 points and the Nasdaq Composite closed at 14,174, up... 
Via Talk Markets
Topics Stocks
Exposures US Equities
64 Biggest Movers From Friday
Gainers Kanzhun Limited (NASDAQ: BZ) shares climbed 95.8% to close at $37.20 on Friday after the company priced its IPO at $19 per share. Novan, Inc. (NASDAQ: NOVN) shares gained... 
Via Benzinga
Topics Initial Public Offering
Exposures Securities Market
Biotechs Ready To Roar
The biggest event last week was the FDA decision to approve Biogen's drug aducanumab, a treatment for Alzheimer's disease. The decision will reverberate across the industry and the healthcare sector... 
Via Talk Markets
Exposures Product Safety
46 Stocks Moving In Friday's Mid-Day Session
Gainers Kanzhun Limited (NASDAQ: BZ) shares surged 77.4% to $33.70 after the company priced its IPO at $19 per share. Novan, Inc. (NASDAQ: NOVN) shares jumped 73.3% to $15.67... 
Via Benzinga
Topics Initial Public Offering
Exposures Securities Market
8 Health Care Stocks Showing Unusual Options Activity In Today's Session
This unusual options alert can help traders track potentially big trading opportunities. Traders often look for circumstances when the market estimation of an option diverges away... 
Via Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
Gainers Novan (NASDAQ:NOVN) stock rose 71.04% to $15.46 during Friday's regular session. As of 12:30 EST, Novan's stock is trading at a volume of 109.3 million,... 
Via Benzinga
28 Stocks Moving in Friday's Pre-Market Session
Gainers Amesite Inc. (NASDAQ: AMST) rose 138% to $6.60 in pre-market trading after surging over 25% on Thursday. Chemomab Therapeutics Ltd. (NASDAQ: CMMB) rose 37.5% to $27.50... 
Via Benzinga
Ignore Biogen: 3 Reasons These Stocks Will Be Better Alzheimer's Investments
Data doesn't lie. These companies have the potential to quickly steal the spotlight. 
Via The Motley Fool
Exposures Product Safety
Biogen Snagged: Will Hefty Price Tag Hinder Alzheimer's Drug Use?
Biogen stock dipped Tuesday as analysts questioned how much use its potential blockbuster Alzheimer's treatment, Aduhelm, would ultimately secure. 
Via Investor's Business Daily
Why Centene Stock Was Up 19% in May
New executives and confirmation that an acquisition will close soon sparked a rally in the shares. 
Via The Motley Fool
Why Cassava Sciences Was Up 15% in May
Thanks to key funding, its Alzheimer's drug is on track even after Biogen's historic approval. 
Via The Motley Fool
Forget Biogen: These 2 Alzheimer's Drug Stocks Could Make You Rich
There are better options for investors looking to profit from potential Alzheimer's disease treatments. 
Via The Motley Fool
Exposures Product Safety
Biogen Wins Landmark Alzheimer's Approval: 5 Things To Know About Aducanumab
The FDA approved Biogen's Alzheimer's treatment, aducanumab, on Monday — though Biogen stock remained halted into the long-awaited decision. 
Via Investor's Business Daily
Exposures Product Safety
Annovis Bio Stock Rockets As Alzheimer's Drug Tops Biogen, Cassava Sciences
Annovis Bio said Friday its experimental Alzheimer's and Parkinson's treatment improved cognition in less than a month, leading ANVS stock to soar. 
Via Investor's Business Daily
The Fight Against Alzheimer's Reaches A Moment Of Truth For Biogen, Other Biotech Stocks
The FDA will soon review aducanumab, possibly the first new Alzheimer's treatment in years. Stakes are high for Biogen stock — and other biotech stocks too. 
Via Investor's Business Daily
Exposures Product Safety
Betting Big On What Could Be The Next Great Biotech Boom
Via FinancialNewsMedia
Caladrius Biosciences, Cassava Sciences Secure Non-Dilutive Funding For Product Development
Caladrius Biosciences Inc (NASDAQ: CLBS) has received $1.4 million in non-dilutive funding as an approved participant of the Technology Business Tax... 
Via Benzinga
Biden's Budget May Boost These 3 Biotechs
It signals a big push toward curing a neurological disease with a massive market. 
Via The Motley Fool
Exposures COVID-19
Benzinga's Top Ratings Upgrades, Downgrades For April 27, 2021
Upgrades According to JP Morgan, the prior rating for BP Midstream Partners LP (NYSE:BPMP) was changed from Neutral to Overweight. For the fourth quarter, BP Midstream... 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Gainers Aldeyra Therapeutics (NASDAQ:ALDX) stock moved upwards by 25.29% to $13.92 during Tuesday's pre-market session. The company's market cap stands at $661.8... 
Via Benzinga
Alzheimer's Disease: 5 Stocks on Biotech Radars
What's been interesting for the past couple of years, and especially the last few months, is to watch the rise of emerging, small-cap Biotech companies trying to take on the big AD and other... 
Via Talk Markets
48 Biggest Movers From Yesterday
Gainers Welbilt, Inc. (NYSE: WBT) shares surged 44.5% to close at $22.58 on Wednesday after The Middleby Corporation announced plans to acquire the company. Skillz Inc. (NYSE:... 
Via Benzinga
< Previous 1 2
...
27 28 29 30 31 32 33 34 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.